Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Guardant Health ( (GH) ) is now available.
Guardant Health announced its preliminary, unaudited results for the fourth quarter and full year 2024, reporting a 31% increase in annual revenue driven by strong clinical and biopharma sales. Despite this growth, the company reported a negative free cash flow of $275 million for the full year and cited its strategic focus on expanding its commercial infrastructure following the successful launch of the Shield test, positioning itself for continued growth in the oncology sector.
More about Guardant Health
Guardant Health is a leading precision oncology company that provides blood and tissue tests, real-world data, and AI analytics to transform patient care and accelerate new cancer therapies. Founded in 2012, the company focuses on improving cancer outcomes through early detection, monitoring, and treatment selection across all stages of cancer care.
YTD Price Performance: 15.53%
Average Trading Volume: 1,840,936
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $4.54B
Find detailed analytics on GH stock on TipRanks’ Stock Analysis page.